References
1. Billan S, Kaidar-Person O, Gil Z. Treatment after progression in the
era of immunotherapy. Lancet Oncol (2020) 21(10):e463-e76. doi:
10.1016/S1470-2045(20)30328-4. PubMed PMID: 33002442.
2. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade.Science (2018) 359(6382):1350-5. doi: 10.1126/science.aar4060.
PubMed PMID: 29567705; PubMed Central PMCID: PMCPMC7391259.
3. Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in
Cancer Therapy. J Clin Oncol (2015) 33(17):1974-82. doi:
10.1200/JCO.2014.59.4358. PubMed PMID: 25605845; PubMed Central PMCID:
PMCPMC4980573.
4. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets
TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy
in melanoma patients. Science (2018) 359(6371):97-103. doi:
10.1126/science.aan4236. PubMed PMID: 29097493; PubMed Central PMCID:
PMCPMC5827966.
5. Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillere R, et
al. Gut microbiome influences efficacy of PD-1-based immunotherapy
against epithelial tumors. Science (2018) 359(6371):91-7. doi:
10.1126/science.aan3706. PubMed PMID: 29097494.
6. Schluter J, Peled JU, Taylor BP, Markey KA, Smith M, Taur Y, et al.
The gut microbiota is associated with immune cell dynamics in humans.Nature (2020) 588(7837):303-7. doi: 10.1038/s41586-020-2971-8.
PubMed PMID: 33239790; PubMed Central PMCID: PMCPMC7725892.
7. Geva-Zatorsky N, Sefik E, Kua L, Pasman L, Tan TG, Ortiz-Lopez A, et
al. Mining the Human Gut Microbiota for Immunomodulatory Organisms.Cell (2017) 168(5):928-43 e11. doi: 10.1016/j.cell.2017.01.022.
PubMed PMID: 28215708; PubMed Central PMCID: PMCPMC7774263.
8. Hussain N, Naeem M, Pinato DJ. Concomitant medications and immune
checkpoint inhibitor therapy for cancer: causation or association?Human vaccines & immunotherapeutics (2021) 17(1):55-61. Epub
2020/06/24. doi: 10.1080/21645515.2020.1769398. PubMed PMID: 32574106;
PubMed Central PMCID: PMCPMC7872020.
9. Pinato DJ, Howlett S, Ottaviani D, Urus H, Patel A, Mineo T, et al.
Association of Prior Antibiotic Treatment With Survival and Response to
Immune Checkpoint Inhibitor Therapy in Patients With Cancer. JAMA
Oncol (2019) 5(12):1774-8. doi: 10.1001/jamaoncol.2019.2785. PubMed
PMID: 31513236; PubMed Central PMCID: PMCPMC6743060.
10. Kim H, Lee JE, Hong SH, Lee MA, Kang JH, Kim IH. The effect of
antibiotics on the clinical outcomes of patients with solid cancers
undergoing immune checkpoint inhibitor treatment: a retrospective study.BMC cancer (2019) 19(1):1100. doi: 10.1186/s12885-019-6267-z.
PubMed PMID: 31718585; PubMed Central PMCID: PMCPMC6852740.
11. Ahmed J, Kumar A, Parikh K, Anwar A, Knoll BM, Puccio C, et al. Use
of broad-spectrum antibiotics impacts outcome in patients treated with
immune checkpoint inhibitors. Oncoimmunology (2018)
7(11):e1507670. doi: 10.1080/2162402X.2018.1507670. PubMed PMID:
30377571; PubMed Central PMCID: PMCPMC6205076.
12. Chalabi M, Cardona A, Nagarkar DR, Dhawahir Scala A, Gandara DR,
Rittmeyer A, et al. Efficacy of chemotherapy and atezolizumab in
patients with non-small-cell lung cancer receiving antibiotics and
proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR
trials. Annals of oncology : official journal of the European
Society for Medical Oncology (2020) 31(4):525-31. doi:
10.1016/j.annonc.2020.01.006. PubMed PMID: 32115349.
13. Smelick GS, Heffron TP, Chu L, Dean B, West DA, Duvall SL, et al.
Prevalence of acid-reducing agents (ARA) in cancer populations and ARA
drug-drug interaction potential for molecular targeted agents in
clinical development. Mol Pharm (2013) 10(11):4055-62. doi:
10.1021/mp400403s. PubMed PMID: 24044612.
14. Bruno G, Zaccari P, Rocco G, Scalese G, Panetta C, Porowska B, et
al. Proton pump inhibitors and dysbiosis: Current knowledge and aspects
to be clarified. World J Gastroenterol (2019) 25(22):2706-19.
doi: 10.3748/wjg.v25.i22.2706. PubMed PMID: 31235994; PubMed Central
PMCID: PMCPMC6580352.
15. Jackson MA, Goodrich JK, Maxan ME, Freedberg DE, Abrams JA, Poole
AC, et al. Proton pump inhibitors alter the composition of the gut
microbiota. Gut (2016) 65(5):749-56. doi:
10.1136/gutjnl-2015-310861. PubMed PMID: 26719299; PubMed Central PMCID:
PMCPMC4853574.
16. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD,
et al. Updating guidance for reporting systematic reviews: development
of the PRISMA 2020 statement. J Clin Epidemiol (2021) 134:103-12.
doi: 10.1016/j.jclinepi.2021.02.003. PubMed PMID: 33577987.
17. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the
assessment of the quality of nonrandomized studies in meta-analyses.Eur J Epidemiol (2010) 25(9):603-5. doi:
10.1007/s10654-010-9491-z. PubMed PMID: 20652370.
18. Higgins JP, Thompson SG. Quantifying heterogeneity in a
meta-analysis. Stat Med (2002) 21(11):1539-58. doi:
10.1002/sim.1186. PubMed PMID: 12111919.
19. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring
inconsistency in meta-analyses. BMJ (2003) 327(7414):557-60. doi:
10.1136/bmj.327.7414.557. PubMed PMID: 12958120; PubMed Central PMCID:
PMCPMC192859.
20. Begg CB, Mazumdar M. Operating characteristics of a rank correlation
test for publication bias. Biometrics (1994) 50(4):1088-101.
PubMed PMID: 7786990.
21. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis
detected by a simple, graphical test. BMJ (1997)
315(7109):629-34. doi: 10.1136/bmj.315.7109.629. PubMed PMID: 9310563;
PubMed Central PMCID: PMCPMC2127453.
22. Afzal MZ, Shirai K. What impact do the proton pump inhibitors have
on the efficacy of immune check point inhibitors in metastatic malignant
melanoma? Journal of Clinical Oncology (2019) 37. doi:
10.1200/JCO.2019.37.15_suppl.e21040.
23. Husain M, Xu M, Patel S, Johns A, Grogan M, Li M, et al. Proton pump
inhibitor use (PPI) in patients treated with immune checkpoint
inhibitors (ICI) for advanced cancer: Survival and prior therapy.Journal of Clinical Oncology (2021) 39(15 SUPPL). doi:
10.1200/JCO.2021.39.15_suppl.2633.
24. Peng K, Chen K, Teply BA, Yee GC, Farazi PA, Lyden ER. Impact of
Proton Pump Inhibitor Use on the Effectiveness of Immune Checkpoint
Inhibitors in Advanced Cancer Patients. The Annals of
pharmacotherapy (2021):10600280211033938. Epub 2021/07/21. doi:
10.1177/10600280211033938. PubMed PMID: 34282636.
25. Cortellini A, Tucci M, Adamo V, Stucci LS, Russo A, Tanda ET, et al.
Integrated analysis of concomitant medications and oncological outcomes
from PD-1/PD-L1 checkpoint inhibitors in clinical practice.Journal for immunotherapy of cancer (2020) 8(2). Epub 2020/11/07.
doi: 10.1136/jitc-2020-001361. PubMed PMID: 33154150; PubMed Central
PMCID: PMCPMC7646355.
26. Iglesias-Santamaría A. Impact of antibiotic use and other
concomitant medications on the efficacy of immune checkpoint inhibitors
in patients with advanced cancer. Clinical & translational
oncology : official publication of the Federation of Spanish Oncology
Societies and of the National Cancer Institute of Mexico (2020)
22(9):1481-90. Epub 2020/01/11. doi: 10.1007/s12094-019-02282-w. PubMed
PMID: 31919759.
27. Svaton M, Zemanova M, Zemanova P, Kultan J, Fischer O, Skrickova J,
et al. Impact of Concomitant Medication Administered at the Time of
Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung
Cancer. Anticancer research (2020) 40(4):2209-17. Epub
2020/04/03. doi: 10.21873/anticanres.14182. PubMed PMID: 32234916.
28. Cortellini A, Di Maio M, Nigro O, Leonetti A, Cortinovis DL, Aerts
JG, et al. Differential influence of antibiotic therapy and other
medications on oncological outcomes of patients with non-small cell lung
cancer treated with first-line pembrolizumab versus cytotoxic
chemotherapy. Journal for immunotherapy of cancer (2021) 9(4).
Epub 2021/04/09. doi: 10.1136/jitc-2021-002421. PubMed PMID: 33827906;
PubMed Central PMCID: PMCPMC8031700.
29. Gaucher L, Adda L, Séjourné A, Joachim C, Guillaume C, Poulet C, et
al. Associations between dysbiosis-inducing drugs, overall survival and
tumor response in patients treated with immune checkpoint inhibitors.Therapeutic advances in medical oncology (2021)
13:17588359211000591. Epub 2021/04/03. doi: 10.1177/17588359211000591.
PubMed PMID: 33796151; PubMed Central PMCID: PMCPMC7968039.
30. Ruiz-Bañobre J, Molina-Díaz A, Fernández-Calvo O, Fernández-Núñez N,
Medina-Colmenero A, Santomé L, et al. Rethinking prognostic factors in
locally advanced or metastatic urothelial carcinoma in the immune
checkpoint blockade era: a multicenter retrospective study. ESMO
open (2021) 6(2):100090. Epub 2021/03/20. doi:
10.1016/j.esmoop.2021.100090. PubMed PMID: 33740735; PubMed Central
PMCID: PMCPMC7980066.
31. Buti S, Bersanelli M, Perrone F, Tiseo M, Tucci M, Adamo V, et al.
Effect of concomitant medications with immune-modulatory properties on
the outcomes of patients with advanced cancer treated with immune
checkpoint inhibitors: development and validation of a novel prognostic
index. European Journal of Cancer (2021) 142:18-28. doi:
10.1016/j.ejca.2020.09.033.
32. Zhao S, Gao G, Li W, Li X, Zhao C, Jiang T, et al. Antibiotics are
associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in
Chinese patients with advanced non-small cell lung cancer. Lung
cancer (Amsterdam, Netherlands) (2019) 130:10-7. Epub 2019/03/20. doi:
10.1016/j.lungcan.2019.01.017. PubMed PMID: 30885328.
33. Hopkins AM, Kichenadasse G, Karapetis CS, Rowland A, Sorich MJ.
Concomitant proton pump inhibitor use and survival in urothelial
carcinoma treated with atezolizumab. Clinical Cancer Research(2020) 26(20):5487-93. doi: 10.1158/1078-0432.CCR-20-1876.
34. Jun T, Ozbek U, Dharmapuri S, Hardy-Abeloos C, Zhu H, Lin JY, et al.
Antacid exposure and immunotherapy outcomes among patients with advanced
hepatocellular carcinoma. Therapeutic advances in medical
oncology (2021) 13:17588359211010937. Epub 2021/05/18. doi:
10.1177/17588359211010937. PubMed PMID: 33995594; PubMed Central PMCID:
PMCPMC8107671.
35. Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in
Cancer Immunotherapy. Mol Cancer Ther (2015) 14(4):847-56. doi:
10.1158/1535-7163.MCT-14-0983. PubMed PMID: 25695955.
36. High TMB Predicts Immunotherapy Benefit. Cancer Discov (2018)
8(6):668. doi: 10.1158/2159-8290.CD-NB2018-048. PubMed PMID: 29661758.
37. Routy B, Gopalakrishnan V, Daillere R, Zitvogel L, Wargo JA, Kroemer
G. The gut microbiota influences anticancer immunosurveillance and
general health. Nat Rev Clin Oncol (2018) 15(6):382-96. doi:
10.1038/s41571-018-0006-2. PubMed PMID: 29636538.
38. Uchiyama AAT, Silva PAIA, Lopes MSM, Yen CT, Ricardo ED, Mutão T, et
al. Proton pump inhibitors and oncologic treatment efficacy: A practical
review of the literature for oncologists. Current Oncology (2021)
28(1):783-99. doi: 10.3390/curroncol28010076.
39. Rogers MAM, Aronoff DM. The influence of non-steroidal
anti-inflammatory drugs on the gut microbiome. Clin Microbiol
Infect (2016) 22(2):178 e1- e9. doi: 10.1016/j.cmi.2015.10.003. PubMed
PMID: 26482265; PubMed Central PMCID: PMCPMC4754147.
40. Biswas S, Benedict SH, Lynch SG, LeVine SM. Potential immunological
consequences of pharmacological suppression of gastric acid production
in patients with multiple sclerosis. BMC Med (2012) 10:57. doi:
10.1186/1741-7015-10-57. PubMed PMID: 22676575; PubMed Central PMCID:
PMCPMC3386885.
41. Homicsko K RG, Tuchmann F, Tsourti Z, Hanahan D, Coukos G,
Wind-Rotolo M, Richtig E, Zygoura P, Holler C, et al. Proton pump
inhibitors negatively impact survival of PD-1 inhibitor based therapies
in metastatic melanoma patients. Annals of Oncology (2018) 29:40.
doi: 10.1093/annonc/mdy511.001.
42. Hou F, Pan Z, Yang R, Zhi F, Bi Y. Gold digging: Searching for gut
microbiota that enhances antitumor immunity. J Cell Physiol(2021) 236(8):5495-511. doi: 10.1002/jcp.30272. PubMed PMID: 33452716.
43. Li C, Xia Z, Li A, Meng J. The effect of proton pump inhibitor uses
on outcomes for cancer patients treated with immune checkpoint
inhibitors: a meta-analysis. Annals of translational medicine(2020) 8(24). doi: 10.21037/ATM-20-7498.
44. Li M, Zeng C, Yao J, Ge Y, An G. The association between proton pump
inhibitors use and clinical outcome of patients receiving immune
checkpoint inhibitors therapy. International immunopharmacology(2020) 88. doi: 10.1016/j.intimp.2020.106972.
45. Zeng W, Finlayson AE, Shankar S, de Bruyn W, Godman B. Prescribing
efficiency of proton pump inhibitors in China: influence and future
directions. BMC Health Serv Res (2015) 15:11. doi:
10.1186/s12913-014-0638-6. PubMed PMID: 25609265; PubMed Central PMCID:
PMCPMC4308879.
46. Lanas A. We Are Using Too Many PPIs, and We Need to Stop: A European
Perspective. Am J Gastroenterol (2016) 111(8):1085-6. doi:
10.1038/ajg.2016.166. PubMed PMID: 27166129.
47. Mazer-Amirshahi M, Mullins PM, van den Anker J, Meltzer A, Pines JM.
Rising rates of proton pump inhibitor prescribing in US emergency
departments. Am J Emerg Med (2014) 32(6):618-22. doi:
10.1016/j.ajem.2014.03.019. PubMed PMID: 24721025.
48. Tvingsholm SA, Dehlendorff C, Osterlind K, Friis S, Jaattela M.
Proton pump inhibitor use and cancer mortality. Int J Cancer(2018) 143(6):1315-26. doi: 10.1002/ijc.31529. PubMed PMID: 29658114;
PubMed Central PMCID: PMCPMC7611279.